Pharmaceutical

Can supermarket pharmacies plug urgent healthcare gaps?

Can supermarket pharmacies plug urgent healthcare gaps?

Jun 18, 2024

As Asda sets up a nationwide retail pharmacy in the UK and US grocer pharmacies ...

Santa Ana Bio secures $168m for inflammatory disease treatments

Santa Ana Bio secures $168m for inflammatory disease tr...

Jun 16, 2024

Precision immunology company Santa Ana Bio has announced a substantial funding i...

Suven Pharmaceuticals to gain controlling stake in Sapala Organics

Suven Pharmaceuticals to gain controlling stake in Sapa...

Jun 16, 2024

India-based Suven Pharmaceuticals has announced a definitive agreement to acquir...

AbbVie and FutureGen link on inflammatory bowel disease

AbbVie and FutureGen link on inflammatory bowel disease

Jun 16, 2024

AbbVie has made a licence agreement with FutureGen Biopharmaceutical for develop...

UK’s new Netflix-style funding model for antibiotics goes live

UK’s new Netflix-style funding model for antibiotics go...

Jun 16, 2024

After a successful trial, the UK NHS has become the first to permanently adopt a...

Takeda signs option agreement with Ascentage for CML drug

Takeda signs option agreement with Ascentage for CML drug

Jun 16, 2024

If exercised, the option would allow Takeda to license the TKI olverembatinib ou...

Pre-diabetes rates increase amidst a renaissance for type 2 diabetes research

Pre-diabetes rates increase amidst a renaissance for ty...

Jun 16, 2024

England’s NHS has reported an 18% increase in the number of people with non-diab...

NPX-267 by NextPoint Therapeutics for Prostate Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Prostate Cancer: ...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Endometrial Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Endometrial Cance...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Cervical Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Cervical Cancer: ...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Renal Cell Carcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Renal Cell Carcin...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Osteosarcoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Osteosarcoma: Lik...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Non-Small Cell Lu...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Transitional Cell...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal...

Jun 14, 2024

NPX-267 is under clinical development by NextPoint Therapeutics and currently in...

PF-07960613 by Pfizer for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval

PF-07960613 by Pfizer for Respiratory Syncytial Virus (...

Jun 14, 2024

PF-07960613 is under clinical development by Pfizer and currently in Phase II fo...

93
94
95
96
97